These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17575132)

  • 41. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
    Meyers S; Lenny N; Sun W; Hiebert SW
    Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
    Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The EVI1 gene in myeloid leukemia.
    Nucifora G
    Leukemia; 1997 Dec; 11(12):2022-31. PubMed ID: 9447815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leukemogenesis of the EVI1/MEL1 gene family.
    Morishita K
    Int J Hematol; 2007 May; 85(4):279-86. PubMed ID: 17483069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EVI1 Impairs myelopoiesis by deregulation of PU.1 function.
    Laricchia-Robbio L; Premanand K; Rinaldi CR; Nucifora G
    Cancer Res; 2009 Feb; 69(4):1633-42. PubMed ID: 19208846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
    Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
    Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of binding sites of EVI1 in mammalian cells.
    Yatsula B; Lin S; Read AJ; Poholek A; Yates K; Yue D; Hui P; Perkins AS
    J Biol Chem; 2005 Sep; 280(35):30712-22. PubMed ID: 16006653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of EVI1 in normal and leukemic cells.
    Buonamici S; Chakraborty S; Senyuk V; Nucifora G
    Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
    Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1044-8. PubMed ID: 8577711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
    Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
    Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos.
    Maki K; Yamagata T; Asai T; Yamazaki I; Oda H; Hirai H; Mitani K
    Blood; 2005 Sep; 106(6):2147-55. PubMed ID: 15914564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
    Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
    Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
    Sitailo S; Sood R; Barton K; Nucifora G
    Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells.
    Kumano K; Kurokawa M
    J Cell Physiol; 2010 Feb; 222(2):282-5. PubMed ID: 19847803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
    Kurokawa M; Mitani K; Imai Y; Ogawa S; Yazaki Y; Hirai H
    Blood; 1998 Dec; 92(11):4003-12. PubMed ID: 9834202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EVI1 and hematopoietic disorders: history and perspectives.
    Nucifora G; Laricchia-Robbio L; Senyuk V
    Gene; 2006 Mar; 368():1-11. PubMed ID: 16314052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. UXT interacts with the transcriptional repressor protein EVI1 and suppresses cell transformation.
    McGilvray R; Walker M; Bartholomew C
    FEBS J; 2007 Aug; 274(15):3960-71. PubMed ID: 17635584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of EVI1 in myeloid malignancies.
    Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
    Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report.
    Tanaka K; Oshikawa G; Akiyama H; Ishida S; Nagao T; Yamamoto M; Miura O
    Oncol Lett; 2017 Jul; 14(1):97-102. PubMed ID: 28693140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.
    Wilson M; Tsakraklides V; Tran M; Xiao YY; Zhang Y; Perkins AS
    J Biol Chem; 2016 Jun; 291(26):13591-607. PubMed ID: 27129260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.